HAVCR2 and non-small cell lung carcinoma: A recently developed TIM-3/PD-1 bispecific antibody, lomvastomig, has demonstrated superior antitumor activity compared with monotherapy in treating αPD-1–resistant NSCLC, and is currently being evaluated in a phase 1 clinical trial in NSCLC patients (112).